The electronic nose (e-nose) is a promising technology as a useful addition to the currently available modalities to achieve lung cancer diagnosis. The e-nose can assess the volatile organic compounds detected in the breath and derived from the cellular metabolism. Volatile organic compounds can be analyzed to identify the individual chemical elements as well as their pattern of expression to reproduce a sensorial combination similar to a fingerprint (breathprint). The e-nose can be used alone, mimicking the combinatorial selectivity of the human olfactory system, or as part of a multisensorial platform. This review analyzes the progress made by investigators interested in this technology as well as the perspectives for its future utilization.
The electric nose (e-nose) reproduces the combinatorial selectivity appropriate to the human olfaction system. Unlike the human nose, gas mixtures are pumped towards the e-nose and, through a sampling device, are filtered to be then exposed to several sensors. In turn, these sensors produce signals which are processed through computerized algorithms based on pattern recognition and multivariate analysis.
1 E-nose technology represents a promising innovation in the field of a "no touch" early diagnosis of lung cancer. 2, 3 In brief, the e-nose works by identifying fingerprints, or breathprints, defined by the activation of gas sensors exposed to volatile organic compounds (VOCs) that are markers of the cellular metabolism which are found in the exhaled breath but also in other organic fluids.
2,3 Several investigators worldwide have already published the results of their preliminary studies yielding high accuracy for the e-nose in distinguishing between malignant and benign pulmonary nodules as well as the potential to identify an adenocarcinoma histotype and even EGFR status.
2,3
The Historic Background of E-Nose Technology
In 1971, Nobel Prize winner Pauling and his associates published what it is considered the first report showing by gas chromatography (GC) the presence of hundreds of chemical volatile compounds in human breath and urine. 4 Subsequent studies have identified several chemical derivatives of oxidative stress (Table 1 ) which can be produced by cancer-induced peroxidation of DNA bases. [5] [6] [7] [8] Crucial to cancer development is the association of oxidative stress and the induction of cytochrome p-450 enzymes (CYP450), a group of oxidase enzymes ( Fig. 1) . 9 In this setting, free radicals and reactive oxygen species (ROS), characterized by an unpaired electron in the outer shell originating from endogenous as well as exogenous sources (i.e., cigarette smoke), can interact with protein and fatty acids to produce VOCs (Fig. 1) . 9 Currently, more than 3000 VOCs have been detected in the human breath. 9 One distinctive feature of VOCs is that they are individually detected in minimal concentrations by sophisticated analytical equipments. 10 Another characteristic of the VOCs is that they are exhaled in human breath according to an equilibrium concentration resulting from their "fat-to-blood'' and ''blood-to-air'' partition coefficients specific to the compartments where these products of cellular metabolism can be interchanged. Accordingly, VOC chemical and physical properties, as well as many physiologic and pathologic conditions, may potentially interfere with the concentration of these compounds both in the alveoli and in the proximal airway. 9 As an example, the specific VOC lipophilic status can affect its diffusion through cell membranes; in fact, less lipophilic VOCs are exchanged in the airway thereby emphasizing the role of the airway in the gas exchange process. 9 In addition, the quantity of VOCs in the alveoli depends from their retention in the lung, in turn directly proportional to the alveolar clearance. 9 The Canine Model of Breath Analysis Canine scent detection has been investigated for several decades due to its potential to identify breath complex chemical compounds present in parts per trillion. 11 In 2006, McCulloch et al. 11 published a trial determining the accuracy of the canine olfactory system of trained household dogs by comparing breath samples from lung and breast cancer patients to healthy individuals. 11 Sensitivity and specificity of the canine olfactory system compared to conventional diagnostic pathways were 99% (95% confidence interval: 99-100) and 99% (95% confidence interval: 96-100), respectively. To curb the enthusiasm for this intriguing modality for early lung cancer detection, two major limitations arguing against routinely using sniffer dogs emerged from subsequent contributions. First, the uncertainty as to which compounds the canine olfactory system may be stimulated by and, second, the unreliable collaborative attitude expressed by the animal due to motivation or other confounding factors. 12 However, the ability of trained dogs to detect lung cancer-related scent patterns represented a novel concept which links canine scent detection to pattern recognition-based models of the currently available e-nose devices. 13 In addition, the use of canine olfactory receptors as a biophysical template to structure e-noses is being investigated (see below). 14 
A Bioengineered Sensorial Platform
The exhaled breath can be analyzed based on two distinct albeit complementary approaches (Fig. 2) 
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: (1) VOC identification, and (2) VOC patterning. The first approach is aimed at identifying characteristic biomarkers associated with specific diseases through selective sensors for VOCs. 9 The instrumentation used to identify individual VOCs is based on the mainstream of analytical chemistry, mainly GC coupled with mass spectrometry (GC-MS). 15 Conversely, the second approach looks for exhaled breath fingerprint through cross-reactive sensors, aiming at defining specific patterns of disease-related VOCs -without proceeding to their individual identification. 9 
VOC Collection and Sampling
VOCs can either be collected by "trapping" (by means of sorbent materials, within a chamber, or dehumidifier) or can be directly delivered to a measurement device (i.e., sensor) (Fig. 3) . 9 VOC collection before delivery exposes several drawbacks ranging from the loss of VOCs to potential contamination of the gaseous sample. 9 Conversely, direct delivery to the measurement unit allows for interaction with the sensor array by inducing either an electrical or optical changes then bound to be transduced into signals. 9 The interaction between VOCs and sensors will be specific or semiselective depending on the need for VOC identification (i.e., selective or lockand-key sensors) as opposed to patterning (i.e., crossreactive sensors). 9 
VOC Analysis and Identification
To analyze VOCs in human breath, the ideal sensors should capture minimal absolute VOC concentrations and variations thereof, rapidly return to baseline status if not exposed to VOCs, and be so easily manufactured and low-priced to be available in large disposable quantities. 9 For VOC identification, the gas sample is transferred into GC-MS where it is analyzed according to the time to elution (i.e., absorption) in the chromatography column and to the mass-to-charge ratio. 15 The quantification of VOCs by GC-MS is an expensive, time-consuming process which demands expert personnel as well as dedicated laboratory facilities.
9,15

VOC Patterning: Sensor Features
From a technical standpoint, the starting point for capturing a signature of the whole exhaled breath consists of the use of a large number of nonselective sensors combined in the so-called sensor arrays. [16] [17] [18] Multiple sensor arrays produce a multidimensional output which is then analyzed with pattern recognition techniques specific to multivariate data analysis. Based on the available gas sensor arrays, dubbed e-noses used by different research groups and enterprises all over the world can be distinguished into the e-nose and the hybrid e-nose. The e-nose group includes the sensor arrays based on conductive materials (i.e., thin oxide, gold nanoparticles, polymers) and electroacoustic sensors (i.e., Quartz Microbalance [QMB] or Surface Acoustic Wave Sensors). 9, [19] [20] [21] [22] [23] [24] [25] The colorimetric sensor arrays represent another category of sensors characterized by exposing the VOCs to a series of chemoresponsive dyes, thereby generating color changes visible by the naked eye or at spectroscopy. 26, 27 The other category of breath analyzers could be called "hybrid e-noses" because these devices are Alternatively, the characteristic patterns of VOCs are recognized through the e-nose technology and linked to specific disease conditions (bottom). Reproduced from van der Schee et a. 15 with permission. VOC, volatile organic compound; GC, gas chromatography; MS, mass spectrometry.
based on the integration of sensor performing according to the traditional methods of the analytical chemistry (i.e., spectroscopic approach) and a fingerprinting approach. 28 To summarize, the best standards for breathprinting are obtained by the following measure chain: (1) a device able to collect exhaled breath onto a cartridge which can be transported and stored; (2) an instrument for desorbing the exhaled breath into the sensor cell; and (3) a versatile sensor system including several nonselective sensing elements able to measure biological exhalates. Currently, two systems seem to abide by the above requirements. The first system is manufactured by Owlstone Inc., who has created a device for exhaled breath sampling known as ReCIVA as well as the Lonestar breath analyser. 7, 17, 29 The latter is a commercially available device based on a hybrid e-nose technology. The second system has been manufactured by a group from the University Campus Bio-Medico of Rome, Italy. It is based on a measure chain including a device for exhaled breath collection on a cartridge known as the Pneumopipe (European patent n. 12425057.2) 30 ; a desorbing unit able to thermally desorb the cartridge content into the sensor cell (known as the Breathstiller); and a gas and liquid sensor array able to analyze the volatile and liquid part of any biological fluid, known as BIO-NOTE. 25 The BIONOTE (BIOsensor-based multisensorial system for mimicking Nose, Tongue and Eyes) comprises in a single device a multisensorial platform aimed at weighing VOCs by using an array of Qujarz microbalance sensors using anthocyanins as chemical interactive material. BIONOTE can also perform the electrochemical or the optical analysis of the liquid part of the patient' sample. 25 The potential use of such multisensorial platform is reported later in this article.
A Bioengineered Sensorial Platform: The Breathprint
Fingerprints can be univocally associated to a single individual for his/her identification. This is a well-known technique based on three fundamental elements: a standard list of features to be used as reference for each comparison, a huge library of individual fingerprints, and an effective method for fingerprinting. Similarly, exhaled breath fingerprint (also known as breathprint) should define the individual health-state, as preconized by several studies in the last twenty years. [31] [32] [33] [34] [35] [36] The breathprint is obtained in the presence of a device for breathprint capturing (collection and measurement), a method for its analysis and a breathprint library. [37] [38] [39] As a consequence, the refinement in the implementation of these three principals have marked the evolution of breathprinting technology. As an example, the methods used for exhaled breath collection have accounted for the influence of the environment background, the selection of the exhaled breath volume to be sampled, and the duration and modality of sampling (i.e., blowing as opposed to normal breathing). 39 Also, some confounding and/or influential factors, such as smoking, food intake, and other habits, have been considered to evaluate and possibly limit their effects on the collected sample. 39 Exhaled breath collection can be performed with a direct delivery of the exhalate from the subject into the device measurement cell, or with an indirect modality by using sampling media. 30 The latter technique is the most frequently used, whereas sampling bags or adsorbing cartridges are the two most frequently used media. 39 Obviously, the selection of the sampling medium plays an important role with respect to its subsequent analysis as it contributes to amplifying, diluting, or modifying the sample itself. From a patient point of view, breathing into a device which autonomously conveys the sample in a cartridge is less invasive than breathing into a bag. Moreover, from an experimental point of view, the possibility of storing and transporting exhaled breath samples in a cartridge instead of a fragile (in terms of variability) bag represents an added value. Finally, from a technical point of view, the use of a preconcentration technique (i.e., through an adsorbing cartridge) improves the sensor sensitivity offering a better resolution at low concentration values. In addition, an ad hoc device aimed at collecting the exhaled breath into a cartridge must be manufactured. Currently, three such devices are available for clinical use, one made by the University Campus Bio-Medico of Rome, Italy, one by the Menssana research team, and one from Owlstone Inc. 16, 17, 30, 40 Results of Breathprinting in NonNeoplastic Conditions E-nose technology has been proven to have important discriminatory and classificatory properties in several mainly respiratory chronic diseases. A breathprint easily distinguishes asthma from chronic obstructive pulmonary disease patients and from controls. 31, 41, 42 Besides differing from that of controls, the breathprint also distinguishes cirrhotic from noncirrhotic patients and significantly changes in patients with decompensated liver cirrhosis. 43, 44 At a 2-year follow-up examination, two breathprint patterns corresponding to the largest and the smallest amounts of produced VOCs were associated with the worst survival, adding to the prognostic capacity of traditional indexes such as the Child Plug category. 44 E-nose technology has been successfully used to distinguish patients with several neurologic and mental disorders from controls. 35, [45] [46] [47] [48] Experience from patients with nonmalignant conditions has emphasized the potentially significant impact of age, gender, and comorbidities on the reproducibility of e-nose measurements to facilitate an unconfounded estimation of cancer-related breathprint. 49, 50 In this setting, e-nose technology might also surrogate spirometry in people who are unable to comply with the rigorous procedural standards of spirometry. In fact, in approximately one of four people older than 65 years, spirometry cannot be completed mainly due to illiteracy, sarcopenia, severe bronchial obstruction, or cognitive impairment. 51 
Results of Breathprinting for Early Diagnosis of Lung Cancer
In an effort to achieve an early diagnosis of lung cancer, many studies were aimed at validating noninvasive diagnostic methods to find an effective test for screening high-risk populations (Table 2 ). In 2011, investigators of the National Lung Screening Trial reported a 20% reduction in lung cancer-specific mortality by using low-dose computed tomography (LDCT) to screen populations at high risk for developing lung cancer. 52 Radiation exposure, the occurrence of false-positive results leading to unnecessary invasive diagnostic procedures and the reported over-diagnosis of slowgrowing tumors, along with the paradoxical encouragement of smoking represent potential arguments against the implementation of LDCT screening. [53] [54] [55] Strategies for reducing false positives resulting from LDCT screening consist of the periodic revision of the guidelines for the interpretation and management of nodules (i.e., volumetric assessment of the nodule) and the research of possible complementary biomarkers. 56, 57 In this setting, many studies tried to validate the efficacy of the assessment of VOCs in the exhaled breath as a diagnostic tool for lung cancer. In 2012, Ehmann et al. 58 published an interesting paper in which they analyzed the capability of four trained family dogs in detecting lung cancer. Their study was a prospective, blinded, clinical trial in which dogs produced 125 breath samples yielding an overall sensitivity of 71% and a specificity of 93%, thus confirming the existence of a scent pattern associated with lung cancer. 58 Expectedly, one major limitation of this study was the low reproducibility of the test. In the past decades, several artificial olfaction systems (i.e., e-nose technology) based on nonselective chemical sensors aimed at measuring and comparing VOC patterns (breathprint) have been proposed in the literature to obtain a precise identification of the compounds observed in exhaled breath of lung cancer patients. 38, 59 Such technologies differ from each other in Adca, adenocarcinoma; Squam, squamous cell carcinoma; GC-MS, gas chromatography-mass spectrometry.
many respects, from the working principle to the sensing material and the array composition. In 2015, McWilliams et al. 60 collected and analyzed breath samples both from lung cancer patients and high-risk smokers without cancer. The investigators found that with the e-nose device known as the Cyranose 320 they could distinguish lung cancer patients from high-risk control subjects with a better than 80% accuracy, thereby concluding that e-nose technology could be used as a noninvasive tool for screening individuals at increased risk for lung cancer. 60 Later, Rocco et al. 61 validated an artificial olfactory system called BIONOTE to detect lung cancer in patients who were enrolled in a lung cancer screening program. The investigators examined 100 individuals who were considered high-risk for lung cancer with the BIONOTE yielding an overall sensitivity and specificity of 86% and 95%, respectively, thereby delineating a substantial difference between breathprints from lung cancer patients as opposed to healthy individuals. 61 In 2012, Barash et al. 62 used gold nanoparticle sensors to distinguish VOCs from cell lines of healthy individuals compared to different lung cancer histotypes. The investigators succeeded in discriminating between lung carcinoma and healthy cells, between NCLC and SCLC cells, and between adenocarcinoma and squamous cell carcinoma with an accuracy ranging between 9% and 96%. 62 In addition, the possibility to identify genetic mutations to guide the oncologists' practice was shown by a group of investigators who identified the breathprints associated with EGFR and KRAS mutations as well as with anaplastic lymphoma kinase and p53 rearrangements. 63, 64 Recently, Shlomi et al. 2 reported that patients with early lung cancer could be discriminated from patients with benign pulmonary nodules with a sensitivity, specificity, and accuracy of 75%, 93%, and 87%, respectively. Both positive predictive values and negative predictive values were high (approximately 88%), indicating the efficiency and suitability of the test despite the small number of patients enrolled in the study. 2 Today, the scientific interest in e-nose technology is growing strongly even in the absence of absolute scientific evidence that could drive clinical practice worldwide. Future studies will need to focus on the validating e-nose technology to replicate the same high percentages of specificity and sensitivity reported in the relatively low numbered series. E-nose technology must also be made applicable on a large scale, meaning devices must be user friendly, less expensive, and capable to rapidly yield a "yes/no" result.
Given the available knowledge, several potential applications of e-nose technology could be anticipated. These include the verification of smoking cessation in patients enrolled in lung cancer screening programs along with the ability to identify high-risk individuals for LDCT. 61, 65, 66 In addition, the e-nose could be used to confirm a suspected pulmonary nodule before scheduling an invasive surgical procedure. 2, 25, 38, 67 After surgery, breath analysis may serve to determine if and when to perform a follow-up computed tomographic scan or positron-emission tomography. 61, 68 When surgery is not indicated and a diagnostic biopsy of a suspected lesion would be hazardous, the e-nose can support the clinical algorithms in establishing malignancy before administering alternative treatments, such as stereotactic body radiation therapy. 2, 61, 62 Another interesting perspective is represented by the use of the e-nose to identify lung cancer-related genetic mutations and to support Response Evaluation Criteria in Solid Tumors criteria to assess the response to medical treatments. 2, 69, 70 However, the low number used in the series exploring the value of e-nose technology and the lack of standardized and miniaturized devices enabling physicians to complete the sample collection and data analysis in real time appear to be major limitations to a more diffuse clinical implementation of this technology. In addition, e-nose findings should be confirmed in larger series by ruling out confounders, such as comorbidities and other cancers, for which this technology has shown promising results.
The E-Tongue and Real-Time Breath Analysis
In addition and to complement e-nose technology, another modality of VOC detection through so-called e-tongue technology has been reported. 71 E-tongue devices are meant to use chemometric sensors to identify compounds in liquid samples. 1 In particular, the e-tongue consists of an electronic system controlling several electrodes immersed in a biological fluid.
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Several sensor arrays can be used in this system, including electrochemical, optical, mass and enzymatic sensors. 1 Among the electrochemical sensors, the potentiometric ones measure the potential between two electrodes with no current flow as the effect of free energy change until an equilibrium status is obtained. 1 Conversely, voltammetric sensors can measure the current produced by oxidization or reduction of redox active compounds (i.e., VOCs) with very high sensitivity. 1 In this system, VOCs and other compounds can react with the electrodes at a certain potential given by a cyclic voltage input yielding additional information to complement the multisensorial platform used for lung cancer detection. Nevertheless, although it is theoretically worthy of assessment, the potential contribution of the e-tongue to the multisensorial detection of cancer needs further investigation. VOC, volatile organic compound; pCO 2 , partial pressure of carbon dioxide; GC-MS, gas chromatography-mass spectronomy; GC Â GC, comprehensive two-dimensional gas chromatography.
An intriguing scenario on the use of this technology for exhaled breath fingerprinting is provided by the implementation of real-time breath analysis through proton-transfer-reaction mass spectrometry (PTR-MS), proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF-MS), or selected ion flow tube MS. 9, 73 In these systems, the gas sample interacts with excess ion charges (i.e., hydronium ions), resulting in the attendant transfer of ions to the VOCs which are then analyzed with GC-MS. 15 No need for sample collection or preconcentration procedures is contemplated with the above techniques which, however, remain far from being suitable for routine use in the clinical setting. 74 In this context, two technological developments may pave the way to the development of the entire breath analytic process in a real-time mode: matrix-assisted laserenhanced desorption/ionization and secondary nanoelectrospray ionization MS. 74, 75 These techniques are based on the concept of obtaining ionization of macromolecules contained in VOCs into analytes which are then accelerated into the MS. 74, 75 A major hurdle against the wide implementation of the above techniques into clinical practice is that this instrumentation is bulky and requires complex sampling and pre-concentration methods. 74 In this setting, an important technological advancement is represented by the optical measurements of VOCs through the application of laser absorption techniques to obtain spectral fingerprints expressed in ranges of ultraviolet to mid-infrared frequencies with detection levels ranging from parts per million to parts per billion. 76, 77 Examples of this concept are tunable diode laser absorption spectroscopy (TDLAS) and cavity ringdown spectroscopy (CRDS) with its variants (i.e., integrated cavity output spectroscopy, cavity enhanced absorption spectroscopy, and cavity leak-out absorption spectroscopy). 76 In both TDLAS and CRDS, a laser beam is passed through a gaseous environment where it is incrementally absorbed to yield a decrease of the recorded laser beam intensity. 76 In CRDS, the laser beam is injected into an optical cavity where it is continuously reflected on two opposing mirrors, thus determining the multipass nature of the optical absorption path. 76 The intensity of the light beam decays in proportion to speed of light, mirror reflectivity, and distance between mirrors; if gas is introduced in the optical cavity, the intensity of the light beam decay increases due to the gas-related absorption. 76 Conversion of the light beam signal into an acoustic pattern is the concept on which photoacoustic spectroscopy is based. 76 In brief, the acoustic waves generated by the resonance of the laser frequency interacting with the frequency of the gas molecules are detected by a sensitive microphone, thereby creating a spectral fingerprint. 76 Currently, laser spectroscopic techniques can identify several breath biomarkers and are rapidly becoming commercially available. 76 The Future of Breath Analysis: Proteomics and Neuron-Based Sensors
The vapor phase of the breath sample can be refrigerated to 0 C or transformed into liquid through a condenser. 78, 79 The extraction of human DNA and proteins from exhaled breath condensate has been proposed for genomic and proteomic analysis. 78, 79 Compared to healthy individuals, several exhaled breath condensate biomarkers have shown variable correlation with the stage and the prognosis of the primary tumor including DNA microsatellite alterations, p53 gene mutation, increased concentrations of endothelin-1, tumor necrosis factor-a, interleukin-6, and metalloproteinase 9. 79 Another intriguing perspective is represented by the possibility of integrating olfactory sensory neuron-based sensors into portable e-nose devices. 78, 80 The olfactory receptors (i.e., neurons) are locked into proteins or nanotubes of the sensor array or on its surface serving as the analyte-binding component. 78, 80 By using these neuron-based sensors, the concentration threshold for detection of individual analytes can go as low as 10 -12 M. 78 
Conclusions
As preconized almost 10 years ago, we may soon be witnessing a scenario in which a miniaturized, handheld e-nose device will fit in the lab coat pocket of any clinician involved in lung cancer management, ready to be used based on the radiological suspicion of lung cancer. 33, 81 Despite some obvious limitations (Table 3) , the e-nose may soon become the test to guide and complement further diagnostic workup based on the evidence that it is a low-cost procedure which entails minimal distress for the patient and limited necessary logistics. [81] [82] [83] [84] Because breathprint analysis may help predict the survival of lung cancer patients, protocols aimed at defining response to treatment and posttreatment follow-up procedures may be effectively revolutionized by the introduction of the new generations of laser-based e-nose devices and innovative sensing materials, similar to the spectroscopically encoded resins characterized in their structure by infrared and Raman spectra which are converted to disease-specific bar-codes for rapid interpretation (bar-coded resins). 83, 85 
